Literature DB >> 30372069

Solution Thermodynamics and Kinetics of Metal Complexation with a Hydroxypyridinone Chelator Designed for Thorium-227 Targeted Alpha Therapy.

Gauthier J-P Deblonde1, Trevor D Lohrey1,2, Corwin H Booth1, Korey P Carter1, Bernard F Parker1,2, Åsmund Larsen3, Roger Smeets3, Olav B Ryan3, Alan S Cuthbertson3, Rebecca J Abergel1,4.   

Abstract

The solution chemistry of a chelator developed for 227Th targeted alpha therapy was probed. The compound of interest is an octadentate ligand comprising four N-methyl-3-hydroxy-pyridine-2-one metal-binding units, two tertiary amine groups, and one carboxylate arm appended for bioconjugation. The seven p Ka values of the ligand and the stability constants of complexes formed with Th(IV), Hf(IV), Zr(IV), Gd(III), Eu(III), Al(III), and Fe(III) were determined. The ligand exhibits extreme thermodynamic selectivity toward tetravalent metal ions with a ca. 20 orders of magnitude difference between the formation constant of the Th(IV) species formed at physiological pH, namely [ThL]-, and that of its Eu(III) analogue. Likewise, log β110 values of 41.7 ± 0.3 and 26.9 ± 0.3 (T = 25 °C) were measured for [ThL]- and [FeIIIL]2-, respectively, highlighting the high affinity and selectivity of the ligand for Th ions over potentially competing endogenous metals. Single crystal X-ray analysis of the Fe(III) complex revealed a dinuclear 2:2 metal:chelator complex crystallizing in the space group P1̅. The formation of this dimeric species is likely favored by several intramolecular hydrogen bonds and the protonation state of the chelator in acidic media. LIII edge EXAFS data on the Th(IV) complexes of both the ligand and a monoclonal antibody conjugate revealed the expected mononuclear 1:1 metal:chelator coordination environment. This was also confirmed by high resolution mass spectrometry. Finally, kinetic experiments demonstrated that labeling the bioconjugated ligand with Th(IV) could be achieved and completed after 1 h at room temperature, reinforcing the high suitability of this chelator for 227Th targeted alpha therapy.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30372069     DOI: 10.1021/acs.inorgchem.8b02430

Source DB:  PubMed          Journal:  Inorg Chem        ISSN: 0020-1669            Impact factor:   5.165


  9 in total

1.  Stable Chelation of the Uranyl Ion by Acyclic Hexadentate Ligands: Potential Applications for 230U Targeted α-Therapy.

Authors:  Joshua J Woods; Ryan Unnerstall; Abbie Hasson; Diane S Abou; Valery Radchenko; Daniel L J Thorek; Justin J Wilson
Journal:  Inorg Chem       Date:  2022-02-09       Impact factor: 5.436

2.  Advances in PSMA theranostics.

Authors:  Thomas M Jeitner; John W Babich; James M Kelly
Journal:  Transl Oncol       Date:  2022-05-18       Impact factor: 4.803

Review 3.  Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight".

Authors:  Romain Eychenne; Michel Chérel; Férid Haddad; François Guérard; Jean-François Gestin
Journal:  Pharmaceutics       Date:  2021-06-18       Impact factor: 6.321

4.  Harnessing α-Emitting Radionuclides for Therapy: Radiolabeling Method Review.

Authors:  Hua Yang; Justin J Wilson; Chris Orvig; Yawen Li; D Scott Wilbur; Caterina F Ramogida; Valery Radchenko; Paul Schaffer
Journal:  J Nucl Med       Date:  2021-09-09       Impact factor: 11.082

Review 5.  Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy.

Authors:  Urs B Hagemann; Katrine Wickstroem; Stefanie Hammer; Roger M Bjerke; Sabine Zitzmann-Kolbe; Olav B Ryan; Jenny Karlsson; Arne Scholz; Hartwig Hennekes; Dominik Mumberg; Alan S Cuthbertson
Journal:  Cancer Biother Radiopharm       Date:  2020-04-07       Impact factor: 3.099

6.  Ultra-selective ligand-driven separation of strategic actinides.

Authors:  Gauthier J-P Deblonde; Abel Ricano; Rebecca J Abergel
Journal:  Nat Commun       Date:  2019-06-04       Impact factor: 14.919

7.  Synergistic Effect of a Mesothelin-Targeted 227Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models.

Authors:  Katrine Wickstroem; Urs B Hagemann; Véronique Cruciani; Antje M Wengner; Alexander Kristian; Christine Ellingsen; Gerhard Siemeister; Roger M Bjerke; Jenny Karlsson; Olav B Ryan; Lars Linden; Dominik Mumberg; Karl Ziegelbauer; Alan S Cuthbertson
Journal:  J Nucl Med       Date:  2019-03-08       Impact factor: 10.057

8.  Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with Olaparib in a BRCA2 Deficient Xenograft Model.

Authors:  Katrine Wickstroem; Jenny Karlsson; Christine Ellingsen; Véronique Cruciani; Alexander Kristian; Urs B Hagemann; Roger M Bjerke; Olav B Ryan; Lars Linden; Dominik Mumberg; Michael Brands; Alan Cuthbertson
Journal:  Pharmaceuticals (Basel)       Date:  2019-10-15

Review 9.  Hydroxypyridinones as a Very Promising Platform for Targeted Diagnostic and Therapeutic Radiopharmaceuticals.

Authors:  Xu Zhou; Linlin Dong; Langtao Shen
Journal:  Molecules       Date:  2021-11-19       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.